Patents by Inventor Paul Daniel Donohoue

Paul Daniel Donohoue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210079367
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Application
    Filed: November 13, 2020
    Publication date: March 18, 2021
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • Patent number: 10889808
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Grant
    Filed: March 3, 2019
    Date of Patent: January 12, 2021
    Assignee: Locanabio, Inc.
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • Patent number: 10876101
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: December 29, 2020
    Assignee: Locanabio, Inc.
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • Publication number: 20200318088
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Patent number: 10711258
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: July 14, 2020
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Publication number: 20200208155
    Abstract: The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof. Nucleic acid sequences encoding the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising such nucleic acids, and compositions thereof.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Patent number: 10590415
    Abstract: The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof. Nucleic acid sequences encoding the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising such nucleic acids, and compositions thereof.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: March 17, 2020
    Assignee: Ceribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Publication number: 20200080068
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Application
    Filed: November 22, 2019
    Publication date: March 12, 2020
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • Publication number: 20200071684
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Application
    Filed: November 18, 2019
    Publication date: March 5, 2020
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Patent number: 10501728
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: December 10, 2019
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Publication number: 20190185831
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Application
    Filed: March 3, 2019
    Publication date: June 20, 2019
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • Publication number: 20190112587
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Application
    Filed: December 18, 2018
    Publication date: April 18, 2019
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Publication number: 20190100775
    Abstract: The present disclosure provides engineered polynucleotide sequences that form scaffolds and nucleoprotein complexes comprising such engineered polynucleotide sequences that form scaffolds and nucleic acid binding proteins. Nucleic acid sequences encoding the engineered polynucleotide sequences that form scaffolds, as well as expression cassettes, vectors and cells comprising such polynucleotide sequences, are described. A variety of methods for making and using the engineered polynucleotide sequences that form scaffolds are also disclosed.
    Type: Application
    Filed: October 4, 2018
    Publication date: April 4, 2019
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Publication number: 20190040373
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Application
    Filed: October 20, 2018
    Publication date: February 7, 2019
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Patent number: 10196619
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Grant
    Filed: October 20, 2018
    Date of Patent: February 5, 2019
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Publication number: 20180346894
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Application
    Filed: June 28, 2018
    Publication date: December 6, 2018
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Patent number: 10138472
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: November 27, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Patent number: 10125354
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: November 13, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Patent number: 10125361
    Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: November 13, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: Andrew Paul May, Rachel E. Haurwitz, Jennifer A. Doudna, James M. Berger, Matthew Merrill Carter, Paul Daniel Donohoue
  • Publication number: 20180312827
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Application
    Filed: July 16, 2018
    Publication date: November 1, 2018
    Inventors: Paul Daniel Donohoue, Andrew Paul May